Parthenolide as Cooperating Agent for Anti-Cancer Treatment of Various Malignancies

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Cancer therapy resistance is linked to nuclear factor kappa B (NF-κB) activation.
• Parthenolide (PN) targets NF-κB and other pro-survival pathways.
• PN shows potential in reducing cancer stem-like cells.

Purpose of the Study:

• To review the activity of Parthenolide (PN) in cancer.
• To explore PN's potential as a complementary cancer therapy.
• To summarize PN's role in overcoming cancer resistance.

Main Methods:

• Literature review of existing studies on Parthenolide (PN).
• Analysis of PN's effects on NF-κB signaling and cancer cell apoptosis.
• Examination of PN's synergistic effects with other anti-cancer drugs.

Main Results:

• PN inhibits NF-κB signaling, induces apoptosis, and reduces cancer stem-like cells.
• PN enhances the sensitivity of cancer cells to various therapies.
• PN demonstrates cooperative effects with multiple anti-cancer agents.

Conclusions:

• Parthenolide (PN) is a promising agent for multimodal cancer therapy.
• PN can potentially overcome primary and acquired cancer resistance.
• PN's complementary role in cancer treatment warrants further investigation.